A troubled timeline
Since Purdue Pharma’s top-selling drug, OxyContin, went on sale in the mid-1990s, it has faced growing legal and regulatory scrutiny.
1995: U.S. Food and Drug Administration approves Purdue Pharma’s OxyContin. 1996: OxyContin goes on market. 2001: OxyContin annual sales surpass $1 billion. 2003: U.S. Government Accountability Office details OxyContin’s role in opioid crisis and outlines dubious Purdue marketing practices. The company receives warning letter from FDA about its marketing practices. 2007: Company and three top executives plead guilty to fraudulent marketing and agree to combined $635 million penalty to federal and state authorities. 2010: FDA approves reformulated version of OxyContin. 2015: Purdue reaches $24 million settlement with state of Kentucky related to false marketing claims. 2016: Connecticut joins coalition of 42 states investigating Purdue and other opioid makers and distributors. 2017: Lawsuits mount against company. Thirteen states and many local and county governments file litigation. Department of Justice launches investigation of Purdue.
2018: Litigation against Purdue continues to mount. Eighteen states sue. Total number of lawsuits against company surpasses 1,000.
More than half of American states have filed lawsuits against Purdue Pharma in the past three years. Have not filed a suit against Purdue Have filed a suit against Purdue